What is LOPJLB’s current signal on KLRS?

LOPJLB’s latest quantitative signal on Kalaris Therapeutics Inc (KLRS) is SELL in a CRISIS regime. Signals are updated daily.

What market regime is KLRS in?

Kalaris Therapeutics Inc (KLRS) is currently classified in the CRISIS HMM market regime on LOPJLB.

What does Kalaris Therapeutics Inc (KLRS) do?

Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), as well as for the treatment of other exudative and neovascular reti…

Where is Kalaris Therapeutics Inc based / listed?

Kalaris Therapeutics Inc is based in US, listed on NASDAQ.

Kalaris Therapeutics Inc (KLRS)

COMPARE

Healthcare · Biotechnology · NASDAQ · US

$2.50-2.34%Close

SELLCRISIS · day 23

[SCORES & PROFILE]

FUND: 13
VALUE: 23
GROWTH: 47
GARP: 6
TYPE: Value / Recovery

Composite of Value · Growth · GARP

ROIC-43.0%

REV YoY-

ROE-71.7%

EPS YoY-

ROA-44.5%

GROSS

NET

[VALUATION]

P/E TTM-1.32

P/E FWD-

SECTOR PE20.12

INDUSTRY PE13.79

P/B1.10

P/FCF-

EV/EBITDA-0.36

EV/EBIT-

PEG-

FCF YIELD-

RISK

INT COV-

D/E2.43

ALTMAN Z-

CURR RATIO10.98

ND/EBITDA-

BETA0.21

Kalaris Therapeutics Inc (KLRS)

Key stats

Industry peers

Prediction markets

FUNDAMENTALS

Company news